Presenter: Justin Lenarcic, Senior Wealth Investment Solutions Analyst, Wells Fargo Investment Institute
|Investment and Insurance Products:
- NOT FDIC Insured
- NO Bank Guarantee
- MAY Lose Value
Twenty-five years ago, IBM’s Deep Blue defeated chess grand champion Garry Kasparov and the world took notice of artificial intelligence, or AI. Today, thanks to AI, computers have learned to write poetry, smartphones find the quickest route to the office, and driverless taxis transport passengers in Arizona.
In April 2003, scientists announced the mapping of the entire human genome. Today, doctors are beginning to use gene therapy to treat inherited and acquired disorders and scientists designed the COVID-19 vaccine two days after the virus’s genetic code went public.
Disruptive, transformational technologies like AI and the gene editing breakthrough CRISPR, are entering a new era that likely will impact our lives and drive innovation for decades.
Three key ingredients have converged to propel us into a new era of Artificial Intelligence — big data, faster computers, and machine learning algorithms.
Humans consumed an astonishing amount of data last year, and researchers anticipate data consumption is likely to increase more than two-fold by 2025.
And while only 65% of the world’s population has access to the internet, that percentage increased 10% in just six months last year.
These increases are quickly pushing the bounds of computing power. Super computer processing capacities have increased even faster than anticipated.
The simultaneous increase in both data and computational speed has ignited interest among computer scientists in building algorithms to organize and analyze data — driving a new era of AI.
Global corporations are emphatically embracing this trend.
Using supercomputers to harness the power of data also extends to the fabric of our being — DNA.
Nearly 20 years after the dawn of gene therapy, recent advancements are making it possible for researchers to pinpoint what causes certain diseases, and repair and replace genes via CRISPR. The genomics revolution will help scientists understand and treat some of our biggest health care challenges.
From a high level, we expect the Information Technology and Communication Services sectors to benefit from the modern evolution of AI. Companies with the largest pools of capital and data should prevail among the multiple long-term technology trends.
The Biotechnology sector continues to become increasingly intertwined and reliant on developments within genomics and gene therapy. The sector has seen a significant increase in companies specializing in genomics-related technology.
These firms are low quality and typically struggle mid-late cycle as liquidity begins to evaporate. In the future, these smaller cap firms may present an attractive acquisition opportunity for some of the larger players in the S&P 500.
For more ideas about how to leverage these advancements over the next decade, read our Wells Fargo Investment Institute special report: Transformative technologies — Investment opportunities in artificial intelligence and genomics.
Each asset class has its own risk and return characteristics. The level of risk associated with a particular investment or asset class generally correlates with the level of return the investment or asset class might achieve. Stock markets, especially foreign markets, are volatile. Stock values may fluctuate in response to general economic and market conditions, the prospects of individual companies, and industry sectors. Small- and mid-cap stocks are generally more volatile, subject to greater risks and are less liquid than large company stocks. Sector investing can be more volatile than investments that are broadly diversified over numerous sectors of the economy and will increase a portfolio’s vulnerability to any single economic, political, or regulatory development affecting the sector. This can result in greater price volatility.
The opinions expressed reflect the judgment of the speaker as of the recording date and are subject to change without notice. The material has been prepared or is distributed solely for information purposes and is not a solicitation or an offer to buy any security or instrument or to participate in any trading strategy. Past performance is no guarantee of future results. Additional information is available upon request.
The information contained herein constitutes general information and is not directed to, designed for, or individually tailored to, any particular investor or potential investor. This report is not intended to be a client‐specific suitability or best interest analysis or recommendation, an offer to participate in any investment, or a recommendation to buy, hold or sell securities. Do not use this report as the sole basis for investment decisions. Do not select an asset class or investment product based on performance alone. Consider all relevant information, including your existing portfolio, investment objectives, risk tolerance, liquidity needs and investment time horizon.
Wells Fargo Investment Institute, Inc. is a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A., a bank affiliate of Wells Fargo & Company.
Wells Fargo Advisors is registered with the U.S. Securities and Exchange Commission and the Financial Industry Regulatory Authority, but is not licensed or registered with any financial services regulatory authority outside of the U.S. Non-U.S. residents who maintain U.S.-based financial services account(s) with Wells Fargo Advisors may not be afforded certain protections conferred by legislation and regulations in their country of residence in respect of any investments, investment transactions or communications made with Wells Fargo Advisors.
Wells Fargo Advisors is a trade name used by Wells Fargo Clearing Services, LLC and Wells Fargo Advisors Financial Network, LLC, Members SIPC, separate registered broker-dealers and non-bank affiliates of Wells Fargo & Company.
© 2022 Wells Fargo Investment Institute. All rights reserved.